LeMaitre Vascular (LMAT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for June 2, 2025, at the company’s headquarters in Burlington, MA at 10:00 a.m. EDT.
Proxy materials, including the 2025 Proxy Statement and 2024 Annual Report, are available online for review and voting.
Shareholders are encouraged to vote online or request paper copies of proxy materials by May 23, 2025, for timely delivery.
Voting matters and shareholder proposals
Election of three directors: George W. LeMaitre, David B. Roberts, and Martha Shadan.
Advisory vote to approve 2024 executive compensation for named executive officers.
Advisory vote on the frequency of future say-on-pay votes, with the board recommending every three years.
Ratification of Grant Thornton LLP as independent auditor for fiscal year ending December 31, 2025.
Board of directors and corporate governance
Board recommends voting for all director nominees and all proposals as outlined.
Latest events from LeMaitre Vascular
- Double-digit growth, global expansion, and 15 years of dividend increases drive strong outlook.LMAT
Investor presentation27 Feb 2026 - Q4 2025 delivered strong growth and 2026 guidance calls for 12% sales growth and higher margins.LMAT
Q4 202526 Feb 2026 - Q2 sales up 11%, net income up 46%, gross margin 68.9%, and 2024 guidance raised.LMAT
Q2 20242 Feb 2026 - Q3 2024 sales and EPS surged on pricing, biologics, and direct sales, with raised guidance.LMAT
Q3 202417 Jan 2026 - Double-digit growth, margin expansion, and higher shareholder returns drive 2025 outlook.LMAT
Q4 202423 Dec 2025 - Q1 2025 saw 13% organic sales growth, margin gains, and a raised outlook amid global expansion.LMAT
Q1 202523 Dec 2025 - Annual meeting to vote on directors, executive pay, say-on-pay frequency, and auditor ratification.LMAT
Proxy Filing1 Dec 2025 - Board urges support for three director nominees amid ongoing governance and diversity discussions.LMAT
Proxy Filing1 Dec 2025 - Q2 2025 sales grew 15% to $64.2M, with 70% margin and raised full-year guidance.LMAT
Q2 202523 Nov 2025